Mekenyan, L. http://orcid.org/0000-0001-5271-7423
Karalilova, R. http://orcid.org/0000-0001-8030-0529
Todorov, P. http://orcid.org/0000-0002-9887-6064
Tepeliev, N. http://orcid.org/0000-0002-2915-7859
Batalov, A. http://orcid.org/0000-0001-8857-0574
Article History
Received: 13 January 2023
Accepted: 30 January 2023
First Online: 28 February 2023
Declarations
:
: All authors have completed and submitted the ICMJE Form for Disclosure of Potential Conflicts of Interest. Prof. Anastas Batalov has received consulting fees from Abbvie, Roche, Sandoz, MSD, Novartis, Pfizer, UCB, Boehringer Ingelheim, Eli Lilly, Stada, Janssen. The other authors have no conflict of interest to declare.